Lifesciences investment group Abingworth Bioventures has closed its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. The fund — Abingworth’s 12th invested in companies in Europe and the U.S. —  exceeded its target of $300 million.  The firm has more than $1.2 billion under management. The fund invests broadly across all stages of development, […]